Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
← catalyst calendarNCT07577583 · readout in 4,851 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
32estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2027-05-01 | estimated | When the study began enrolling |
| Primary completion | 2039-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2039-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Mediated Autoimmune Disorders
Intervention
- Other: No Intervention
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Clinically Significant CEI
measured Up to 15 years
Number of Participants With Clinically Significant CEI Based on Severity
measured Up to 15 years
Duration of Clinically Significant CEI
measured Up to 15 years
Time to Onset of Clinically Significant CEI
measured Up to 15 years
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed